Kaleo

Kaléo is a global leader in drug-delivery device technology and auto-injector innovation. View our Community Guidelines:

[Kaleo @kaleo]

@TheEduPatient highlighted two newly published papers exploring challenges in recognizing & treating anaphylaxis in infants & toddlers. The coverage takes a closer look at what the findings could mean for awareness and preparedness. Read the full article: https://t.co/VQqozaGOrO

[Kaleo @kaleo]

Not every medicine is simple to deliver. Higher viscosities and complex formulations can create unique challenges. The Aerio™ Auto-Injector Platform was designed with flexibility in mind to support a range of drug delivery needs. Explore more: https://t.co/KGNk5jYCGe

[Kaleo @kaleo]

Kaléo named a nominee for the Inaugural 2026 Prix Galien Patient First Award in Honor of Michael J. Fox in the Private Sector Initiatives Category.

Read more: https://t.co/TkFCWs67pJ @GalienFdn

[Kaleo @kaleo]

Emergency threats continue to evolve and meeting those challenges requires technologies designed for demanding environments. Learn how Kaléo is working to help advance medical countermeasures for the frontlines.

Learn more: https://t.co/MRbP8sltZJ

[Kaleo @kaleo]

For healthcare professionals: Did you know Kaléo’s Medical Affairs website offers educational & scientific resources on
anaphylaxis? Explore peer-reviewed publications, evidence-based resources, and information to use with patients and
caregivers. https://t.co/oAUXdj17u1

[Kaleo @kaleo]

For the past 25 years, Kaléo has been guided by a simple purpose: showing up for others when it matters most.

Our anniversary video highlights the people, purpose, and responsibility behind our work. #BuiltToTrust

[Kaleo @kaleo]

License Agreement: Amgen obtained a license to certain of Kaléo's patented technology on auto-injectors, reflecting Kaléo's innovative contribution to drug-device technologies.

Read the full announcement: https://t.co/QsQfB3pzBf

[Kaleo @kaleo]

Anaphylaxis can look different in
infants and toddlers, making it harder
to recognize and treat. Two new papers examine potential barriers to timely recognition and treatment, and explore opportunities to improve preparedness. https://t.co/SqvNYxtlBe

#FoodAllergy #Pediatrics

[Kaleo @kaleo]

Summer camp brings new adventures and important conversations for families managing food allergies. Kids with Food Allergies @kfatweets shares practical tips to help campers, caregivers, and staff prepare for a safer summer. Explore the guide: https://t.co/hBo25BCPdl

[Kaleo @kaleo]

We're in San Diego for #BIO2026.

Schedule a meeting through the BIO Partnering system to explore the Aerio™ Auto-Injector Platform—Kaléo's drug-delivery platform, Developed by Patients, for Patients™.

#DrugDelivery #Biotech

[Kaleo @kaleo]

Across the severe allergy landscape, the need for greater awareness and preparedness remains essential. At a time when food allergies are in focus, we’re launching a new initiative centered on real-world experiences. Learn more: https://t.co/qCJX86vzC2

[Kaleo @kaleo]

This Asthma & Allergy Awareness Month, we’re proud to sponsor premiere events for “May Contain,” the award-winning docudrama highlighting the real experiences of children and families navigating food allergies and anaphylaxis.

Learn more: https://t.co/ry0oxYziaz

[Kaleo @kaleo]

Food allergy bullying is more common than many realize & often goes unspoken. As conversations around food allergies continue this May, this episode of The Itch Podcast explores the signs & how to start meaningful conversations with children and schools. https://t.co/81xOIlAg0n

[Kaleo @kaleo]

Food Allergy Awareness Month is here.

FAACT's #InvisibleNoMore campaign offers educational resources and tools to help patients, families, and communities raise awareness of food allergy safety.

Explore the campaign and get involved. https://t.co/Nb9yKFN5wi

[Kaleo @kaleo]

Kaléo’s Medical Affairs team will be attending the Pediatric Academic Societies (PAS) meeting in Boston this April. If you’ll be there, stop by booth 327 to connect.

[Kaleo @kaleo]

The Kaléo team will be at CBRNe Convergence Canada 2026. Attending? Let’s connect about device innovation and real-world usability in critical environments.

[Kaleo @kaleo]

One platform. Three configurations.

The Aerio™ Auto-Injector Platform is designed to meet the highest standards of device function and form while supporting a range of drug delivery needs:
Aerio™Uno
Aerio™Duo
Aerio™Mix

Learn more: https://t.co/KGNk5jYCGe #BuiltToTrust

[Kaleo @kaleo]

One platform. Three configurations.

The Aerio™ Auto-Injector Platform is designed to meet the highest standards of device function and form while supporting a range of drug delivery needs:
Aerio™Uno
Aerio™Duo
Aerio™Mix

Learn more: https://t.co/KGNk5jYCGe #BuiltToTrust

[Kaleo @kaleo]

Recognizing anaphylaxis in infants and toddlers can be challenging since symptoms may look different than in older children. The Recognizing Anaphylaxis in Infants and Toddlers infographic from @AllergyAsthmaHQ outlines what to look for: https://t.co/Tqs5HQfi2B

[Kaleo @kaleo]

Innovation doesn’t start in the lab. It starts with people. From early design to final production, each version of the Aerio™ auto-injector platform is designed to meet the real-world needs of patients and our partners. Learn more: https://t.co/T9LFRZDuHw #BuiltToTrust